Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT05668949 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped PI requested

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: TTI-101
DRUG: Pembrolizumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]